the munich biotech cluster m4 approach towards personalised medicine
DESCRIPTION
EuroBioForum 2012 | 18 April 2012 Presentation by Horst Domdey, Managing Director of BioM Biotech Cluster Development GmbHTRANSCRIPT
www.m4.de
The Munich Biotech Cluster m4 Approach
towards Personalized Medicine"
Horst Domdey BioM
www.m4.de
BioM – Partner for Sustainable Innovation
• Scouting & Incubation • Start-up Consulting • Funding
Academia
Big Pharma
• Partnering
• Seminars & Workshops
• Networking
• Events
SME • Funding
• Partnering
• Business Development
• Networking
• Professional Training
• Events
www.bio-m.org
www.m4.de
The Munich Life Science Cluster
- a Leading Pharma and Biotech Location
CLUSTER-MANAGEMENT
• > 250 life science companies (126 SMEs)
• > 50% of SMEs focus on Tx & Dx
• impressive drug development pipe line
• innovative platform technologies: imaging, genomics, proteomics, kinomics, etc.
• 8 excellent research institutions
• high density in hospitals, study centers
• 27 pharma companies
• 50 CROs
• 30,000 employees in the life sciences and the life science industry (SMEs: 2,850)
• > € 3 bn invested since1996
www.m4.de
0 10 20 30 40 50 60
Preclinic
Phase I
Phase II
Phase III
Market
59
33
36
8
5
Number of Clinical Candidates of Biotech SMEs in the Greater Munich Area,
BioM 2010
Munich‘s Drug Development Pipeline
www.m4.de
Cluster
Management
for Munich
Hospitals
in Munich
Biotech
and Pharma
in Munich
Science
in Munich
4 Strong Partners for Munich
€ 100 mn
Program
on
Personalized
Medicine
www.m4.de
Structure of the m4 Program R
&D
Pro
ject
s
Stru
ctural P
rojects
SP1 – m4 Trial
Service Center
SP2 – m4
Biobank Alliance
SP3 – m4 Data
Integration System
SP4 – m4 Scouting
& Incubation
SP5 – m4
eAcademy
Board
Steering Committee
Representatives from
Academia & Industry
m4-Clustermanagement
BioM
Personalized Medicine
Targeted Therapies
Preclinical
Models
Production Processes
Associated Partners
Academia & Industry
www.m4.de
Clinical Trials Phases I - III Pre Clinic Approval
eAcademy
Master of Translational Science
Executive MBA of Life Science Management
Scouting &
Incubation
special award, scouts,
targeted identification,
active incubation
Biobank Alliance
central access,
legal and ethical harmonization
highest quality standards
Trial Service Center
service and advice
phase I unit
platform service
Data Integration System
information integration
web portal
safety concept
Human Biomaterial Consulting, Recruiting
Transfer of Information
Innovation Human Capital
m4 Strategy: Establishing a Sustainable Infrastructure through Structural Projects
Translational Seed Fund: seed financing opportunities in PM (in progress)
www.m4.de
m4 Scouting & Incubation
• m4 Scouting
Identification of (bio)pharmaceutical research
projects with a high innovationspotential
• m4 Mentor Circle
Professional mentoring by retired experts from
academia and industry
• m4 Award
Regional pre-seed program for innovative
research projects in the field of biomarkers
and drug development
• m4 Incubation
Assisted incubation of the m4 Award projects
www.m4.de
m4 Award
• Bavarian pre-seed program for Personalized Medicine: € 8.5 Mio until 2015
• € 500,000 per project over 2 years; additional € 30,000 for coaching and special advice
• 80 short proposals received until 31st January, 2011
• 28 full length proposals received unti 30th April, 2011
•m4 Award Committee: experts from Biotech, Pharma and Venture Capital
• 5 grants awarded on 18th July, 2011
www.m4.de
Winners of the First Round of the m4 Award
• K-P Hopfner, F Oduncu, G H Fey (LMU):
Triplebodies against AML
• D. Schendel, C Geiger, M Javorović (HMGU):
Individualised Dendritic Cells as Vaccines for
Patients with Hormone-resistant Prostate Cancer
• M Conrad, J A Schick (HMGU):
New Drugs for the Treatment of
Neurodegenerative Diseases
• F Hausch, M Paez-Pereda (MPI Psychiatry):
Development of FKBP51 Specific Molecules
to Treat Depression
• O Ritter (Univ. Würzburg):
Calportin as First Line Treatment of Heart Failure
www.m4.de
m4 Strategy (II): Boosting Innovation through
40 R&D Projects (mostly Cooperations)
Biomarker
Identification & Validation
Companion Diagnostic
Feasibility and Benefit Market
Drug Development Clinical Trials Phase I - III Market Approval
Approval
Value Chain of Personalized Medicine
Preclinic
Validated
Test Kit
Biotech SME
Pharma/Medtech
Industry
Academia / Clinics
PM6
PM10 PM12
PM13
PM 16 PM15
T4
PM1
PM 7
PM 8
PM 17
PM 2
PM9
PM4
PM5
PM 14
T5
T10
T2
T3
T6
T12 T14
T15 T16
P2
P3
PK1
T9
T17
Focus on:
-> new targeted therapeutics
-> innovative therapy concepts
-> identification and validation of biomarkers
by molecular diagnostics and imaging
techniques
-> set up of platform technologies
main indications: oncology, cardiovascular
diseases, chronic lung diseases, autoimmune
diseases and inflammation
www.m4.de
COR-1, a new Drug for the Treatment
of a Severe Form of Heart Failure
COR-1 is a cyclic peptide
which neutralizes
stimulatory autoimmune
antibodies directed against
the beta-adrenergic receptor
mimicking the effect of
natural ligands like
adrenaline and thus leading
to a chronic over-stimulation
of the receptor.
Consequently this leads to
hypertrophy and reduced
function of the heart.
• Ex vivo, COR-1 showed good
efficacy to neutralize anti ß1
receptor autoantibodies.
• In animal models, COR-1
prevented the generation of heart
failure and also reversed existing
heart failure.
• In a placebo-controlled phase
I clinical trial COR-1 was shown
to be well tolerated.
• COR-1 is now being investigated
in a phase II clinical trial; it is
administered to a subgroup of
heart failure patients who have
been stratified by a specific
diagnostic test.
COR-1 – an m4 Lighthouse Project by Corimmun
www.m4.de
m4 – Evolution through Innovation
2010 1996 1984 2020
Winner in the
BioRegio Contest
Munich
Gene Center
Winner in the
Leading Edge Cluster
Competition
m4
International Cluster of Excellence
in Personalized Medicine
www.m4.de
Predictive Biomarkers
- DNA/RNA-omics
- Proteomics
P4 Medicine – Healthcare of the Future
Personalized Stratification of Patients
- Herceptin
- Erbitux
- . . .
Preventive Life Style and Treatment
- Phenylketonuria
- Diabetes
- Cancer
Participatory Informed Decisions
by informed Patients
- 1000$ Genome